JenaValve Technology Receives CE Mark

IRVINE, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve implantation (TAVI) systems (also referred to as TAVR, or transcatheter aortic valve replacement) for the treatment of aortic valve disease, today announced that it has received CE Mark for its TrilogyTM Heart Valve System for the treatment of both aortic regurgitation (AR), also known as aortic insufficiency (AI), and aortic stenosis (AS).